Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy

Texas Heart Institute Journal

Volumn 28, Issue 2, 2001, Pages 142-145

  Lau, Theodore K ^a,b   Leachman, D Richard ^a   Lufschanowski, Roberto ^a  

^a TEXAS HEART INSTITUTE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Anticholesterernic agents; Cerivastatin adverse effects; Gemfibrozil adverse effects; Hydroxyrnethylglutaryl CoA reductase inhibitors adverse effects; Hypertipidemia drug therapy; Rhabdornyotysis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BUMETANIDE; CARVEDILOL; CERIVASTATIN; DIGOXIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POTASSIUM; SIMVASTATIN;

AGED; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; RHABDOMYOLYSIS;

AGED; ANTILIPEMIC AGENTS; DRUG THERAPY, COMBINATION; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIDINES; RHABDOMYOLYSIS; SEVERITY OF ILLNESS INDEX;

EID: 0034951964     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety
2. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy
3. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
4. Fibrates and statins in the treatment of hyperlipidemia: An appraisal of their efficacy and safety
5. Rhabdomyolysis after taking atorvastatin with gemfibrozil
6. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia
7. Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor
8. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
9. Extending therapy options in treating lipid disorders: A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor
10. Cerivastatin
11. Preclinical and clinical pharmacology of cerivastatin
12. Clofibrate-induced acute muscular syndrome
13. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
14. Cerivastatin: A review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolemia
15. Gemfibrozil-induced myopathy
16. Dual hepatic metabolism of cerivastatin - Clarifications
17. Gemfibrozillovastatin therapy for primary hyperlipoproteinemias
18. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
19. Dual bezafibrate-simvastatin therapy for combined hyperlipidemia
20. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia